EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Ultragenyx Aims for FDA Approval for Sanfilippo Gene Therapy Based on Penn Technology
The drug relies on licensed foundational gene therapy technology created in the laboratory of Dr. James Wilson, MD, PhD.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
PCI and PACT Host AI Event for Philly Tech Week
PCI and the Philadelphia Alliance for Capital and Technologies (PACT) jointly presented a recent event called “AI Nexus: Shaping Tomorrow’s Intelligence."
A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease
Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.
Penn Researchers Create Novel mRNA-based Avian Flu Vaccine
Penn Medicine researchers have developed an mRNA vaccine for the H5N1 avian flu using techniques similar to those enabling mRNA-based COVID-19 vaccines.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.